Thus, the median percentage of TILs infiltration was 20% (4–37%) in TNBC (n = 1620 patients), 16% (11–24%) in HER2+ (n = 2410 patients), and 6% (3–12%) in hormone receptor-positive/HER2- BC (n = 929 patients) [15]. The gene discussed is ERBB2; the disease is breast cancer.